^
Association details:
| Biomarker: | NRAS mutation + BRAF mutation |
|---|---|
| Cancer: | Ampulla of Vater Carcinoma |
| Drug Class: | MEK inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MEK inhibitor treatment is effective in a patient with metastatic carcinoma of the ampulla of Vater with BRAF and NRAS mutations shown by next-generation sequencing
Excerpt:
we present a case of an 84-year-old woman...with nonoperable adenocarcinoma originating from the ampulla of Vater...Her tumor was examined by next-generation sequencing, which showed BRAF and NRAS mutations....The patient has been treated with a MEK inhibitor for the last 12 months since diagnosis, with clinical and laboratory improvement and manageable side effects.
DOI:
10.1097/CAD.0000000000000355
